AstraZeneca, Daiichi Sankyo eye first approval for TROP2 drug after PhIII breast cancer success

AstraZeneca and Daiichi Sankyo’s TROP2-targeted antibody-drug conjugate has met a key endpoint in the Phase III TROPION-Breast01 trial, bringing it one step closer to potentially compete against Gilead’s Trodelvy.

TROPION-Breast01 is evaluating the drug candidate, dato-DXd, against investigators’ choice of chemotherapy in 733 patients with previously-treated inoperable or metastatic HR-positive, HER2-negative breast cancer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Donanemab: FDA AdCom will put spotlight on tau enrolment and ARIA concerns

Share this article Eli Lilly said the FDA wants the AdCom to better understand efficacy implications of its unique trial design. Image credit: Shutterstock /

March 21, 2024

Rucaparib camsylate by Pharmaand for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

May 20, 2024

Corrected: Bipartisan IRA fix seeks to align small molecule and biologic negotiation periods

As the biopharma industry has loudly criticized a provision in the Inflation Reduction Act that provides for negotiations to happen sooner for small molecule drugs

February 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.